From - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Human monoclonal antibody that neutralizes Dickkopf-1 (DKK-1). DKK-1 is an antagonist of the Wnt pathway, which regulates differentiation of mesenchymal stem cells (MSC) into osteoblasts and promotes survival of active osteoblasts. Myeloma cells have been observed to overexpress DKK-1, blocking osteoblast differentiation, and promoting bone resorption. By neutralizing DKK-1, it is hypothesized that BHQ880 will promote bone formation and inhibit tumor-associated osteolytic processes.[1]
Route: IV
Extravasation: no information

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.

Patient drug information

No information available.


  1. BHQ880 (Anti-DKK1 Antibody) at Novartis Oncology